Archive
1250 articles, sorted by publication time.
After a decade of cancer treatment and tumors involving multiple organs, an adolescent received TCR-engineered T-cell therapy under compassionate use and currently has no detectable active cancer; this rare and profound response still needs to be confirmed as reproducible in a small clinical trial.
The oversubscribed Series D financing will advance ADVC001, a PSMA-targeted prostate cancer therapy, and expand U.S. manufacturing and isotope supply; the real test is whether its early efficacy can be replicated in later-stage trials.
For high-risk non-muscle-invasive bladder cancer unresponsive to Bacillus Calmette-Guérin therapy, cretostimogene produced durable remissions and the possibility of bladder preservation in a single-arm Phase 3 trial; however, without a randomized control group, its efficacy advantage still requires direct confirmation.
The oversubscribed Series A financing will advance an ophthalmic solution and a second-generation menin inhibitor; the real test is whether computer generation and pharmacokinetic simulation can translate into efficacy in humans.
Trained on more than 20 years of real-world medical data, the model outperformed multiple benchmarks across 156 diagnostic tasks and a one-week prospective test; however, it missed 21 patients with critical imaging findings, showing that it still has some way to go before independent deployment.
Researchers directed lipid nanoparticles bearing anti-CD34 antibodies to the bone marrow, achieving sustained reactivation of fetal hemoglobin and improved neutrophil production in two humanized mouse models. The findings overcome one barrier to in vivo delivery, but multiple challenges remain before the approach can replace ex vivo stem cell therapy.
Among 44 patients whose disease progressed after receiving daraxonrasib, more than half developed new RAS pathway abnormalities; the most common was not a secondary KRAS mutation, but amplification of the existing mutated gene.
In a randomized trial of 91 AQP4 antibody-positive patients, obinutuzumab β reduced the proportion of patients who relapsed from 45.7% to 4.4%; the results were strong, but the study’s size, follow-up duration, and lack of an active-drug comparator still limit their interpretation.
Ivonescimab plus chemotherapy produced signals of durable efficacy in a small first-line trial, with outcomes not clearly limited by PD-L1 expression levels; however, the single-arm design and high proportion of severe adverse events mean that the true benefit must still be confirmed in a randomized phase 3 trial.
The FDA will convene experts to reassess the combination of RP1 and nivolumab; the meeting concerns not only a new cancer drug, but also whether a single-arm trial and intratumoral injections can adequately demonstrate systemic efficacy.
The early-stage clinical company is betting on epigenetically switching off PCSK9 over the long term, aiming to lower bad cholesterol with a single treatment; funding is now in place, but the real test will be the first human data in 2027.
AbCellera announced preliminary results from a 92-person randomized trial showing that ABCL635 substantially reduced moderate to severe menopausal hot flashes within four weeks, with no serious adverse events observed; however, the full data have not yet been disclosed, and how long the efficacy can be maintained remains to be confirmed.